Prognosis of Patients with Primary Systemic Amyloidosis Who Present with Dominant Neuropathy 11Supported in part by the Quade Amyloidosis Research Foundation and Program Project Grant No. CA 62242, National Cancer Institute (National Institutes of Health).
- 1 March 1998
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 104 (3) , 232-237
- https://doi.org/10.1016/s0002-9343(98)00037-0
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Phase II trial of recombinant interferon alfa‐2 in the treatment of primary systemic amyloidosisAmerican Journal of Hematology, 1993
- Phase II trial of α‐tocopherol (vitamin E) in the treatment of primary systemic amyloidosisAmerican Journal of Hematology, 1990
- Multivariate survival analysis using Cox's regression modelHepatology, 1987
- The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathyMuscle & Nerve, 1983
- The natural history of peripheral neuropathy in primary systemic amyloidosisAnnals of Neurology, 1979
- AMYLOIDOSIS: REVIEW OP 236 CASESMedicine, 1975
- NEUROPATHY, M COMPONENTS, AND AMYLOIDThe Lancet, 1975
- PERIPHERAL NERVE CHANGES IN AMYLOID NEUROPATHYBrain, 1974
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- A CASE OF PRIMARY GENERALIZED AMYLOID DISEASE WITH INVOLVEMENT OF THE NERVESBrain, 1938